Biomarkers for virus-induced hepatocellular carcinoma (HCC)

Mathew, Shilu; Ali, Ashraf; Abdel-Hafiz, Hany A.; Fatima, Kaneez; Suhail, Mohd; Archunan, ‪Govindaraju; Begum, Naheeda; Jahangir, Syed; Ilyas, Muhammad; Chaudhary, Adeel G.; Qahtani, Mohammad Al; Bazarah, Salem M.; Qadri, Ishtiaq

doi:10.1016/j.meegid.2014.06.014

Cited by 27 publications

(19 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the last decade, numerous novel biomarkers were identified due to the advances in genomics and proteomics techniques. These biomarkers are being developed not only for use of HCC diagnosis, but also in prediction of patient and treatment outcomes and individualization of therapy [4–6]. Some of them are more promising, such as glypican-3(GPC3) [7], osteopontin(OPN) [8], Des-γ-carboxyprothrombin(DCP) [9], Golgi protein-73(GP73) [10] and microRNAs (miR-122 and miR-21, et al) [11, 12].…”

Section: Introductionmentioning

confidence: 99%

Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma

Pan

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Members of the metallothionein (MT) family are involved in metal detoxifcation and in the protection of cells against certain electrophilic carcinogens. In present study, it was found that MT1M was downregulated in more than 77.1% (91/118) of hepatocellular carcinoma (HCC) tissues compared with adjacent non-tumor tissues. Furthermore, overexpression of MT1M inhibited cell viability, colony formation, cell migration and invasion in HCC cell lines and tumor cell growth in xenograft nude mice, and activated cell apoptosis in HCC cell lines. In addition, immunohistochemistry analysis showed MT1M was negative or weak staining in tumor tissues but moderate or strong staining in adjacent non-tumor tissues. The sensitivity and specificity of MT1M for HCC diagnosis were 76.27% and 89.83%, respectively. In conclusion, MT1M was identified as a potential tumor marker for HCC and may serve as a useful therapeutic agent for HCC gene therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma

Pan

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…All these liver diseases are still seriously endangering the health of people, while the serum markers of these diseases are far from satisfactory. For HCC especially, the sensitivity and the specificity of AFP, used as a biomarker for the diagnosis, are limited [1]. Imaging techniques often lack specificity in distinguishing dysplastic nodules or cirrhotic macro nodules from HCC [2].…”

Section: Introductionmentioning

confidence: 99%

The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases

Fang

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…With a high death rate attributed to high mortality and unsatisfactory treatment options, hepatocellular carcinoma (HCC) is one of the most prevalent malignant cancers worldwide [1][2][3]. So effective therapeutic tools, such as gene therapy, should be developed for HCC treatment.…”

Section: Introductionmentioning

confidence: 99%

miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression

Peng

You

et al. 2015

Experimental Cell Research

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at post-transcriptional level. miRNA dysregulation plays a causal role in cancer progression. In this study, miR-208-3p was highly expressed and directly repressed ARID2 expression. As a result, ARID2 expression in hepatocellular carcinoma (HCC) was decreased. In vitro, miR-208-3p down-regulation and ARID2 over-expression elicited similar inhibitory effects on HCC cell proliferation and invasion. In vivo test results revealed that miR-208-3p down-regulation inhibited HCC tumorigenesis in Hep3B cells. Moreover, ARID2 was possibly a downstream element of transforming growth factor beta1 (TGFβ1)/miR-208-3p/ARID2 regulatory pathway. These findings suggested that miR-208-3p up-regulation is associated with HCC cell progression and may provide a new target for liver cancer treatment.

show abstract

Biomarkers for virus-induced hepatocellular carcinoma (HCC)

Cited by 27 publications

References 126 publications

Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma

Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma

The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases

miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression

Contact Info

Product

Resources

About